Cellular mechanism of Tβ4 intervention in liver fibrosis by regulating NF-κB signaling pathway.

Zhu ZX, Zhu LL, Cheng Z, Zhao XK, Liu YM, Fan LD, Zou GL, Ouyang QY, Cheng ML

European review for medical and pharmacological sciences1 Feb 2019Cited by 7 (Europe PMC)

PMID30779097DOI10.26355/eurrev_201902_17023PepBankPUB-30779097

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, Tβ4 treatment increased the number of cells in G0/G1 phase arrest compared with the model group and the siRNA-Tβ4 knockdown group.
In plain wordsIn liver cells, thymosin beta‑4 increased cells arrested in the G0/G1 phase compared with IL-1β-treated cells and Tβ4-knockdown cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCells in G0/G1 phase arrest
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Comparator
IL-1β model group and siRNA-Tβ4 knockdown group
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
Due to the G0/G1 phase arrest, the number of cells in the Tβ4 treatment group increased, compared with the model group and the siRNA-Tβ4 knockdown group (p<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909701
02LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, the apoptotic rate in the Tβ4 treatment group increased significantly compared with the model group and the siRNA-Tβ4 knockdown group.
In plain wordsIn liver cells, thymosin beta‑4 raised the rate of cell death compared with IL-1β-treated cells and Tβ4-knockdown cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseApoptotic rate
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Comparator
IL-1β model group and siRNA-Tβ4 knockdown group
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
Due to the G0/G1 phase arrest, the number of cells in the Tβ4 treatment group increased, compared with the model group and the siRNA-Tβ4 knockdown group (p<0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
In the same between-group comparison, apoptotic rate in the Tβ4 treatment group increased significantly (p<0.05).
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909702
03LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, cellular nucleic acid levels of p-IKB were lower in the Tβ4 treatment group than in the siRNA-Tβ4 knockdown group.
In plain wordsIn liver cells, thymosin beta‑4 lowered p-IKB nucleic acid levels compared with cells with Tβ4 knocked down.
Peptide
Thymosin beta-4 (human)
Outcome
Decreasep-IKB nucleic acid level
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Comparator
siRNA-Tβ4 knockdown group
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
The cellular nucleic acid levels of p-IKB and NF-κB/p65 were remarkably lower in the Tβ4 treatment group than in the siRNA-Tβ4 knockdown group (p<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909703
04LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, cellular nucleic acid levels of NF-κB/p65 were lower in the Tβ4 treatment group than in the siRNA-Tβ4 knockdown group.
In plain wordsIn liver cells, thymosin beta‑4 lowered NF-κB/p65 nucleic acid levels compared with cells with Tβ4 knocked down.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseNF-κB/p65 nucleic acid level
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Comparator
siRNA-Tβ4 knockdown group
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
The cellular nucleic acid levels of p-IKB and NF-κB/p65 were remarkably lower in the Tβ4 treatment group than in the siRNA-Tβ4 knockdown group (p<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909704
05LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, expression of NF-κB/p65 was significantly lower in the Tβ4 treatment group.
In plain wordsIn liver cells, thymosin beta‑4 lowered NF-κB/p65 expression.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseNF-κB/p65 expression
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
The expression levels of NF-κB/p65 and NF-κB/p50 were significantly lower in the Tβ4 treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909705
06LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, expression of NF-κB/p50 was significantly lower in the Tβ4 treatment group.
In plain wordsIn liver cells, thymosin beta‑4 lowered NF-κB/p50 expression.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseNF-κB/p50 expression
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
The expression levels of NF-κB/p65 and NF-κB/p50 were significantly lower in the Tβ4 treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909706
07LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, cytoplasmic p-IKB levels were lower in the Tβ4 treatment group than in the model group.
In plain wordsIn liver cells, thymosin beta‑4 lowered cytoplasmic p-IKB compared with IL-1β-treated cells without Tβ4.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseCytoplasmic p-IKB level
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Comparator
IL-1β model group
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
The expression levels of cytoplasmic p-IKB and nuclear NF-κB/p65 were lower in the Tβ4 treatment group than in the model group (p<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909707
08LabIn vitro (cells)Mechanism
In IL-1β-stimulated human hepatic stellate cells, nuclear NF-κB/p65 levels were lower in the Tβ4 treatment group than in the model group.
In plain wordsIn liver cells, thymosin beta‑4 lowered nuclear NF-κB/p65 compared with IL-1β-treated cells without Tβ4.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseNuclear NF-κB/p65 level
Study
humann: not reported in source
HSC-LX2 human hepatic stellate cell line with IL-1β
Comparator
IL-1β model group
Outcome group
Liver fat and liver function · Liver
Studied dose
1000 ng/mlAs given in this study (human).
Source sentences
Summary
The expression levels of cytoplasmic p-IKB and nuclear NF-κB/p65 were lower in the Tβ4 treatment group than in the model group (p<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the inhibitory effect of thymosin-β4 (Tβ4) on the activation of the human hepatic stellate cell line (HSC-LX2) induced by interleukin (IL)-1β.
Summary · context
There were 5 groups in this study, i.e., blank control group, negative control group (SI-NC, empty plasmid), model group (20 ng/ml of IL-1β), siRNA-Tβ4 knockdown group (IL-1β and si-Tβ4) and Tβ4 treatment group (IL-1β and 1000 ng/ml of Tβ4).
Report a problemFND-3077909708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.